Kornimate/medical-research-clean huggingface dataset:
effects of escitalopram on autonomic reactivity in post traumatic stress disorder

Conditions: PTSD

Summary: the study looked at relationship between escitalopram and heart rate variability and qt variability in veterans with ptsd.

the investigators are studying if taking escitalopram will normalize heart rate variability and a decrease (or no effect implying a lack of serious cardiac side effects) including qt variability in veterans with ptsd.

Eligibility criteria:
inclusion criteria: * inclusion criteria - group i * patients, men and women between 19 and 55 years of age, inclusive. * patients with diagnosis of posttraumatic stress disorder as determined by mini-international neuropsychiatric interview (m.i.n.i.). * patients, who are able to comprehend and satisfactorily comply with protocol requirements and have an ability to read and write english. * patients, who signed the written informed consent given prior to entering any study procedure. * inclusion criteria - group ii * patients, men and women between 19 and 55 years of age, inclusive. * patients with diagnosis of major depression as determined by mini-international neuropsychiatric interview (m.i.n.i.). a diagnosis of ptsd will be exclusionary. * patients, who are able to comprehend and satisfactorily comply with protocol requirements and have an ability to read and write english. * patients, who signed the written informed consent given prior to entering any study procedure. exclusion criteria: * history of cardiovascular disease or a history of hypertension. * patients with a concurrent diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) diagnosis in any of the following categories as determined by the m.i.n.i. * lifetime schizophrenia and schizoaffective disorder * lifetime bipolar i disorder * substance dependence or abuse (excluding nicotine) within one month prior to the screening visit. * patients with a history of intolerance or hypersensitivity to escitalopram or citalopram. * patients who based on history or mental status examination have a significant risk of committing suicide. current suicide risk (past month) will be assessed using the m.i.n.i. suicidality module. subjects considered at high suicide risk based on the module (\> 17 points) will be excluded from study participation. * patients who are homicidal or violent and who are in the investigator's opinion in significant imminent risk of hurting others. * subjects will be excluded who have a history of significant medical illness and who are on medications that affect cardiac and/or autonomic function. * female patients who are pregnant, planning to become pregnant, or if of childbearing potential, not using an acceptable method of birth control.
effectiveness of metronidazole in pain control posthemorrhoidectomy

Conditions: Hemorrhoids

Summary: hemorrhoidal disease occurs in 50% of people over 40 years old and is the most common cause of anorectal surgery. one of the complications of hemorrhoidectomy is pain, which is a difficult symptom to appreciate and assess, by its frequent and large variations in sensitivity in each patient. many studies have been done to reduce patient postoperative pain, but there is no ideal method. the application of both oral and topical metronidazole has shown to decrease pain following hemorrhoidectomy, but its use is not standardized. the investigators evaluated the effect of oral administration of metronidazole versus homologated placebo in pain control after hemorrhoidectomy

objective: evaluate the effect of oral administration of metronidazole versus homologated placebo in pain control after hemorrhoidectomy. material and methods: controlled clinical trial, composed of 44 patients in a randomized manner, realized at the coloproctology, western medical center, mexican institute of social security. referred beneficiaries adults were included, of either sex, who merited elective hemorrhoidectomy for hemorrhoidal disease grades iii-iv using ferguson's technique. they were assigned to receive metronidazole (study group) or homologated (control group) and the randomization was conducted by sealed envelopes and subsequently. we collected demographic and clinical variables. postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days; additional analgesic use; complications; return to normal activity and patient satisfaction; also were measured, in a blood sample after surgery and 12 hrs later, interleukin 6 and 10. the statistical analysis was performed according to the nature of variables, for continuous data using measures of central tendency and dispersion and for the qualitative data with frequencies and percentages

Eligibility criteria:
inclusion criteria: * hemorrhoidal disease grade iii and iv * informed consent exclusion criteria: * pregnancy * lactation * other anorectal disease * previous anorectal * hypersensibility to metronidazole

Keywords: hemorrhoidectomy postoperative pain metronidazole
medicaid disenrollment: intrastate emergency department impact

Conditions: Medicaid Enrollment Status

Summary: we will obtain data from the robust agency for healthcare reimbursement and quality (ahrq) healthcare utilization project (hcup), as well as from the state of tennessee. if our hypotheses are true, such data will provide strong evidence that medicaid disenrollment has a negetive health impact on uninsured populations. the data may also provide evidence for increased public funding of safety-net eds after medicaid disenrollment.


Eligibility criteria:
inclusion criteria: * data will be obtained from the agency for healthcare reimbursement and quality (ahrq) healthcare utilization project (hcup) exclusion criteria: * n/a

Keywords: medicaid disenrollment
mindfulness in endometrial and cervical cancer

Conditions: Gynecologic Cancer; Endometrial Cancer; Cervical Cancer; Quality of Life; Opioid Use

Summary: patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to utilize the headspace smartphone application or not prior to their anticipated treatment.

a diagnosis of cancer can be a major stress-inducing event. the prevalence of depression in patients diagnosed with cancer is estimated up to 16%. practicing mindfulness is a cost-effective treatment which can also help manage treatment adverse effects and cancer-related symptoms. even short exposure and practice of mindfulness exercises have demonstrated improved subjective and objective measurements of stress and anxiety with breast biopsies. patients with breast cancer also have improved quality of life with mindfulness training. self-guided mindfulness with smartphone applications, specifically the app headspace, has been associated with positive benefits and ease of use in the general population and among cancer patients. a patient's inherent level of baseline mindfulness has been associated with lower pain scores following minimally invasive hysterectomy. this study did not specifically encourage practice of mindfulness exercises. our own study of post-operative opiate usage in women following minimally invasive hysterectomy contains self-reported data of women using opiates to relax or help sleep. this suggests that mindfulness exercises may improve quality of life in these areas and thus reduce opiate usage. patients undergoing minimally invasive hysterectomy for treatment of endometrial cancer were specifically chosen as a study cohort to build on our own data and that currently reported in the literature as well as the highest incidence of this cancer as a gynecologic malignancy. the second study cohort chosen was women with cervical cancer undergoing definitive treatment with chemo-sensitizing radiation given the significant endeavor required for complete treatment. additionally, these women are often younger with the diagnosis of cervical cancer often being their first major medical diagnosis.

Eligibility criteria:
inclusion criteria: * new diagnosis of either 1) endometrial cancer undergoing surgery or 2) cervical cancer undergoing chemo-sensitizing radiation * access to a smartphone exclusion criteria: * non-english speaking * no access to smartphone * current use of headspace application
p4o2 ild extension

Conditions: Interstitial Lung Disease; Pulmonary Fibrosis; Interstitial Lung Fibrosis; IPF; Pulmonary Fibrosis, Idiopathic; Pulmonary Fibrosis Idiopathic Familial; Chronic Hypersensitivity Pneumonitis; Unclassifiable ILD; Idiopathic NSIP; CTD-ILD

Summary: the goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (ppf) in participants with interstitial lung diseases (ilds). the participant population includes adults diagnosed with idiopathic pulmonary fibrosis (ipf), familial pulmonary fibrosis (fpf), other fibrotic ilds, and interstitial lung abnormalities (ila). the main questions it aims to answer are: * what biomarkers and risk factors are linked to fibrosis progression or can predict rapid worsening and sudden flare-ups in ipf and fpf patients? * what biomarkers and risk factors can predict the development of a ppf phenotype in different types of ild? * what biomarkers and risk factors can help identify ila patients who may develop significant ild? * what biomarkers and risk factors can predict how well ild patients will respond to treatment? researchers will compare the outcomes between participants diagnosed with ipf/fpf, other fibrotic ilds, and ila to see if early detection biomarkers differ among these groups. participants will: * undergo blood sampling. * perform lung function tests. * have ct scans. * perform breath analysis * participate in exposome and microbiome analyses. * complete questionnaires. * a subgroup of participants will be offered bronchoscopy.

included participants will complete several study visits to collect clinical data and biological samples. study visits will be performed at baseline, 3, 6, 12, 24, 36, 48 and 60 months, with a 2-month time window for follow-up visits. these time points are aligned with the standard clinical follow-up visits outlined in the ild care path protocol of amsterdam umc.

Eligibility criteria:
inclusion criteria: * diagnosis of (1) idiopathic pulmonary fibrosis (ipf), familial pulmonary fibrosis (fpf), (2) other fibrotic ilds (fild), including fibrotic hypersensitivity pneumonitis (fhp), idiopathic non-specific interstitial pneumonia (insip), connective tissue disease (ctd)-ild, and unclassifiable ild (uild); or (3) interstitial lung abnormalities (ila). * meeting all the following criteria during the screening period: 1. fvc ≥45% predicted. 2. fev1/fvc ≥0.7. 3. dlco corrected for hb ≥40% predicted. * able to provide written informed consent as approved by the independent ethics committee. * able to undergo a ct scan and perform pft. * age \&gt; 18 years and \&lt; 80 years. * understanding of the dutch or english language. exclusion criteria: * combined pulmonary fibrosis and emphysema (cpfe) diagnosis * chronic obstructive lung disease (copd) with an fev1/fvc \&lt;70%. * uncontrolled severe asthma. * active malignancy, except for squamous cell carcinoma of the skin, low-risk breast cancer, and low-risk prostate cancer. * pregnancy or lactating.

Keywords: interstitial lung disease interstitial lung abnormalities progressive pulmonary fibrosis
perception of time by individuals with eating disorders

Conditions: Feeding and Eating Disorders

Summary: the objective of the study was to determine how patients with eating disorders perceive time, and in particular whether their experience of time differs from that of healthy individuals. another goal was to examine the relationship between the mood of the subjects and their time perspective. the subjects were 30 women with eating disorders and 30 age-matched healthy female controls. the three measures applied were: the time metaphors questionnaire by sobol-kwapinska, the time perspective inventory by zimbardo, and the uwist mood adjective checklist (umacl) by matthews et al.

the objective of the study was to determine how individuals with eating disorders perceive time, and in particular whether their experience of time differs from that of healthy persons. another aim was to investigate the relationship between the mood of the subjects and their time perception as well as determine a variable moderating that relationship. first, it was expected that eating-disordered patients experience time as a rather aversive and unfriendly force marked with chaos and void, in contrast to healthy subjects, who were predicted to treat it as something more friendly, appreciating its subtleties and the significance of the moment (hypothesis 1). moreover, it was expected that individuals with eating disorders would exhibit a more negative temporal orientation, whether past or present, as compared to healthy controls, who would reveal more positive past, present, or future orientations (hypothesis 2). finally, it was predicted that eating disorders moderate the relationship between mood and time perception (hypothesis 3). the study encompassed 30 women with eating disorders (19 patients with anorexia nervosa and 11 patients with bulimia nervosa) and 30 age-matched normal healthy controls. the clinical group consisted of patients of the residential eating disorder therapeutic center "drzewo zycia" in malawa as well as some outpatient clinics in poland; some of the patients were not being actively treated at the time of the study. the controls included psychology students from two polish universities (the cardinal stefan wyszynski university and the university of finance and management, both in warsaw), as well as researchers and educators who volunteered for the study. the three measures applied in the study were: * the time metaphors questionnaire by sobol-kwapinska; * time perspective inventory by zimbardo (zimbardo \& boyd, 1999; see also zimbardo \& boyd, 2009); * the uwist mood adjective checklist (umacl) (matthews at al.; see also gorynska, 2005).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of eating disorders (anorexia nervosa or bulimia nervosa) * age between 18 and 40 years exclusion criteria: * diagnosis of other (except eating disorders) mental disorder * age below 18 years and above 40 years

Keywords: perception of time eating disorders ego-syntonicity existential suffering psychotherapy
evaluation of atuna racemosa toxicity

Conditions: Bacterial Infections

Summary: for thousands of years people in the south pacific have used atuna racemosa extract as a topical anti-inflammatory. we, the researchers at the mayo clinic, have shown this extract to also have antibacterial properties. while this extract has been used for decades in the south pacific, a controlled clinical trial to evaluate toxicity has never been performed.


Eligibility criteria:
the subjects will be 20 healthy male and non-pregnant, non-lactating, female volunteers of ages 18 - 65. no subject will be excluded based on minority status.
camrelizumab plus pyrotinib plus chemotherapy in human epidermal growth factor receptor 2 positive (her2+) advanced gastric or gastroesophageal junction (gej) adenocarcinoma

Conditions: Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma

Summary: this study is designed to evaluate the efficacy and safety of camrelizumab plus pyrotinib in combination with chemotherapy in patients with her2-positive gastric cancer.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older. 2. histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic her2 positive gastric or gej adenocarcinoma. 3. patients have not received systemic treatment in the past but had disease progression more than 6 months after receiving neoadjuvant therapy or the last of adjuvant therapy could be enrolled or failure of first-line therapy or completion of (new) adjuvant therapy to disease recurrence less than 6 months. 4. her2-positive defined as either immunohistochemistry (ihc) 3+ or ihc 2+ in combination with fluorescent in-situ hybridization (fish+ is defined as her2:cep17 ratio≥2.0), as assessed by central review on primary or metastatic tumor. 5. ecog performance status 0-1. 6. at least one measurable lesion exists as defined by recist 1.1 . 7. life expectancy of more than 12 weeks. exclusion criteria: 1. hypersensitivity to camrelizumab, pyrotinib and study chemotherapy agents and/or to any components. 2. has received prior therapy with an anti-pd-1, anti-pd-l1, or anti pd l2 agent or with an agent directed to another stimulatory or co-inhibitory t-cell receptor (e.g., cytotoxic t-lymphocyte-associated protein 4 \[ctla-4\], ox 40, cluster of differentiation 137 \[cd137\]). 3. has an active autoimmune disease that has required systemic treatment in past 2 years. 4. has a known history of human immunodeficiency virus (hiv) or active hepatitis b and c virus infection. 5. has had major surgery within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment. 6. subjects who can not interrupt the using of the drugs that may cause qt prolongation during study. 7. evidence or history of coagulation disorders such as a grade ≥ 3 (ctc-ae) bleeding event. 8. known history of psychotropic substance abuse or drug use.
effects of igf-i in hiv metabolic disease

Conditions: HIV Lipodystrophy

Summary: this study examines the effects of recombinant insulin like growth factor - i on body composition, glucose homeostasis, and lipids, in adults with hiv infection and signs of metabolic disease.

the main objectives of this study are the following: 1. determine the effect of recombinant human insulin like growth factor-i (rhigf-i) (generic: mecasermin) on subcutaneous adiposity in patients with hiv lipodystrophy syndrome. 2. determine the effects of rhigf-i on glucose homeostasis and lipids in patients with hiv lipodystrophy. 3. determine the effects of rhigf-i on apoptosis, mitochondria, and inflammation, in adipose tissue obtained from patients with hiv lipodystrophy.

Eligibility criteria:
inclusion criteria: * hiv positive with undetectable viral load * no change in antiretrovirals for 3 months * evidence of lipoatrophy in the limbs, and face or gluteal area * dyslipidemia defined as: * fasting triglycerides \> 200 or * hdl cholesterol \< 40 mg/dl * abnormal glucose homeostasis defined as: * fasting hyperinsulinemia \> 20 uu/ml or * fasting glucose 100-125 mg/dl, inclusive exclusion criteria: * two consecutive viral \>75 or \> 50 copies/ml using the tests listed above * presence of aids wasting * change in antiretroviral medication (not dose) in the prior 3 months * coronary artery disease, cerebrovascular, or peripheral arterial disease * diabetes mellitus * adrenal insufficiency, hypoglycemia, thyroid disease, or other endocrine disorder that is untreated * malignancy * eating disorder * pregnancy (urine pregnancy test is required of all females) * previous liposuction or bariatric surgery * other systemic conditions or other disorders at the discretion of the investigators * current use of systemic glucocorticoids, or other agent affecting body weight or glucose homeostasis or other drug at the discretion of the investigators * use of interferon within the past six months * use of insulin, insulin secretagogue, thiazolidinedione, or metformin in the prior 3 months * initiation or dose adjustment, within the prior 3 months, of any of the following drugs or drug classes: fibrate, cholesterol binding resin, statin, niacin, or omega 3 fatty acid (fish oil). * use of uridine, growth hormone, igf-i, and growth hormone releasing factor analogues

Keywords: hiv lipodystrophy
study of variations of pleural and esophageal pressures under mechanical ventilation after lung transplantation

Conditions: Respiratory Disease

Summary: the primary objective of the study is to determine the correlation between mean pleural pressure and oesophageal pressure in the immediate aftermath of bi-pulmonary transplantation. in this research, oesophageal pressure will be measured by a nasogastric tube with an esophageal balloon (also suitable for feeding the patient) usually installed at the time of transplantation, pleural pressure will be measured by several pleurocath-type catheters (prodimed inc, france) which the thoracic surgeon will have positioned at the end of the surgery without additional skin intrusion.

pulmonary transplantation is a model of acute lung injury due to ischemia-reperfusion phenomena responsible in 1 in 4 patients for the occurrence of primary graft dysfunction (dpg), which penalizes graft prognosis in the short to medium term. the survival of transplant patients. furthermore, the post-operative period is a complex period in which multiple hemorrhagic, immunological, infectious, and neuromuscular complications may arise that may require prolonged mechanical ventilation. at present, there are no data on the measurement of pressure in pleural space after pulmonary transplantation. achieving this measurement would make it possible to adapt the settings of the ventilator to both the acute phase in the case of dpg and to a later phase in case of mechanical weaning. in the case of bi-pulmonary transplantation, before the thorax is closed, each patient benefits from the systematic placement of bilateral anterior and posterior thoracic drains to prevent the formation of fluid effusions (hemothorax, pleurisy) and / or gases (pneumothorax ) which would impede ventilation and compromise gas exchange. these drains are gradually withdrawn during resuscitation usually after weaning mechanical ventilation

Eligibility criteria:
inclusion criteria: - adult patient admitted in the respiratory distress and severe infections intensive care unit in the postoperative period following a double lung transplant after written informed consent. exclusion criteria: * age less than 18 years, pregnancy, breast feeding, adults under guardianship or under safeguard justice, not beneficiaries of a social security scheme, persons deprived of liberty by a judicial or administrative decision , those hospitalized without consent single lung transplant * open chest at the end of transplantation * high flow pleura-pulmonary fistula (contraindication to the establishment of a nasogastric tube proven presence of esophageal varices esophageal tumor surgery of the esophagus of less than 1 year